

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma

Plot Your Own Course

Resources

Resource	Description	Link
Clinical Trials	BLC2001: Loriot Y, et al. <i>N Engl J Med.</i> 2019;381:338-348.	https://pubmed.ncbi.nlm.nih.gov/31340094/
	EV-201: Petrylak DP, et al. <i>J Clin Oncol.</i> 2019;37(18 Suppl):4505.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.18_suppl.LBA4505
	KEYNOTE-045: Bellmunt J, et al. <i>N Engl J Med.</i> 2017;376:1015-1026.	https://pubmed.ncbi.nlm.nih.gov/28212060/
	JAVELIN Bladder 100: Powles T, et al. <i>N Engl J Med.</i> 2020;383:1218-1230	https://pubmed.ncbi.nlm.nih.gov/32945632/
Guidelines	ESMO: ESMO Guidelines Committee. eUpdate — Bladder Cancer Treatment Recommendations. Published 16 July 2020.	https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations3
	NCCN: Bladder Cancer, V6.2020—July 16, 2020	https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
	WHO/AJCC: Bladder Cancer Staging Update Wang G, McKenney JK. <i>Arch Pathol Lab Med.</i> 2019;143:571-577.	https://pubmed.ncbi.nlm.nih.gov/30044124/
	WHO: 2016 Classification of Urinary System Tumors Humphrey PA, et al. <i>Eur Urol.</i> 2016;70:106-119.	https://pubmed.ncbi.nlm.nih.gov/26996659/
Managing irAEs	Friedman CF, et al. <i>JAMA Oncol.</i> 2016;2:1346-1353.	https://pubmed.ncbi.nlm.nih.gov/27367787/
	Puzanov I, et al. <i>J Immunotherapy Cancer.</i> 2017;5:95.	https://www.ncbi.nlm.nih.gov/pubmed/29972759
Package Inserts	Avelumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s009lbl.pdf
	Enfortumab vedotin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf
	Erdafitinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf
	Pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s084lbl.pdf